216 related articles for article (PubMed ID: 19334379)
21. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia.
Wiederhold NP; Coyle EA; Raad II; Prince RA; Lewis RE
J Antimicrob Chemother; 2005 May; 55(5):792-5. PubMed ID: 15814598
[TBL] [Abstract][Full Text] [Related]
22. [In vitro activity of linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus].
Pérez L; Alarcón T; Jiménez S; de Las Cuevas MC; López-Brea S
Rev Esp Quimioter; 2001 Mar; 14(1):47-50. PubMed ID: 11376349
[TBL] [Abstract][Full Text] [Related]
23. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
24. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.
Henwood CJ; Livermore DM; Johnson AP; James D; Warner M; Gardiner A
J Antimicrob Chemother; 2000 Dec; 46(6):931-40. PubMed ID: 11102412
[TBL] [Abstract][Full Text] [Related]
26. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
Munckhof WJ; Giles C; Turnidge JD
J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
[TBL] [Abstract][Full Text] [Related]
27. Surveillance of linezolid resistance in Germany, 2001-2002.
Brauers J; Kresken M; Hafner D; Shah PM;
Clin Microbiol Infect; 2005 Jan; 11(1):39-46. PubMed ID: 15649302
[TBL] [Abstract][Full Text] [Related]
28. Comparison of in vitro efficacy of linezolid and vancomycin by determining their minimum inhibitory concentrations against methicillin resistant Staphylococcus aureus (MRSA).
Kaleem F; Usman J; Khalid A; Hassan A; Omair M
J Pak Med Assoc; 2011 Apr; 61(4):356-9. PubMed ID: 21465972
[TBL] [Abstract][Full Text] [Related]
29. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.
Stefani S; Mezzatesta ML; Tempera G; Debbra E; Schito AM; Nicoletti G; Marchére A
Clin Microbiol Infect; 2002 Jun; 8(6):368-72. PubMed ID: 12084106
[TBL] [Abstract][Full Text] [Related]
30. Linezolid alone and in combination with rifampicin prevents experimental vascular graft infection due to methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Sacar M; Sacar S; Kaleli I; Onem G; Turgut H; Goksin I; Ozcan V; Kaan Inan B; Duver H; Baltalarli A
J Surg Res; 2007 May; 139(2):170-5. PubMed ID: 17292421
[TBL] [Abstract][Full Text] [Related]
31. [Sensitivity of methicillin resistant staphylococci to linezolid and some other antimicrobial agents].
Ertek M; Yazgi H; Aktaş E; Ayyildiz A; Parlak M
Mikrobiyol Bul; 2003 Oct; 37(4):235-40. PubMed ID: 14748259
[TBL] [Abstract][Full Text] [Related]
32. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.
Yong D; Yum JH; Lee K; Chong Y; Choi SH; Rhee JK
Antimicrob Agents Chemother; 2004 Jan; 48(1):352-7. PubMed ID: 14693566
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of daptomycin & linezolid against methicillin resistant Staphylococcus aureus & vancomycin resistant enterococci isolated from hospitalized cases in Central India.
Chitnis S; Katara G; Hemvani N; Pareek S; Chitnis DS
Indian J Med Res; 2013 Jan; 137(1):191-6. PubMed ID: 23481072
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates.
Candel FJ; Morales G; Picazo JJ
Rev Esp Quimioter; 2011 Sep; 24(3):127-30. PubMed ID: 21947094
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
[TBL] [Abstract][Full Text] [Related]
36. Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections.
Miró-Canturri A; Vila-Domínguez A; Caretero-Ledesma M; Ayerbe-Algaba R; Pachón J; Jiménez-Mejías ME; Smani Y
Microbiol Spectr; 2021 Oct; 9(2):e0040321. PubMed ID: 34668743
[TBL] [Abstract][Full Text] [Related]
37. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program.
Mutnick AH; Enne V; Jones RN
Ann Pharmacother; 2003 Jun; 37(6):769-74. PubMed ID: 12773059
[TBL] [Abstract][Full Text] [Related]
38. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
39. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
Hosgor-Limoncu M; Ermertcan S; Tasli H; Yurtman AN
West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951
[TBL] [Abstract][Full Text] [Related]
40. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
